Skip to main content

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association

Related Videos

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?

How do slow dose titration strategies for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira) potentially affect the side effects seen?

How do slow dose titration strategies for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira) potentially affect the side effects seen?

How do slow dose titration strategies for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira) potentially affect the side effects seen?

What is your current perspective on the LEADER Trial and how should we translate its findings to the front lines of diabetes care? Can you describe the trial design?

What is your current perspective on the LEADER Trial and how should we translate its findings to the front lines of diabetes care? Can you describe the trial design?

What is your current perspective on the LEADER Trial and how should we translate its findings to the front lines of diabetes care? Can you describe the trial design?

What insights have we gained about drug-based management of the diabetic heart?

What insights have we gained about drug-based management of the diabetic heart?

What insights have we gained about drug-based management of the diabetic heart?

From a translational perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

From a translational perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

From a translational perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

Are there significant clinical differences—pharmacokinetic, safety, degree of weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

Are there significant clinical differences—pharmacokinetic, safety, degree of weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

Are there significant clinical differences—pharmacokinetic, safety, degree of weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

Why do clinicians managing patients with T2D need to be aware of the trials, physiologic basis, side effects and other dimensions of deploying fixed ratio, long-acting insulin-GLP-1 RA combination regimens?

Why do clinicians managing patients with T2D need to be aware of the trials, physiologic basis, side effects and other dimensions of deploying fixed ratio, long-acting insulin-GLP-1 RA combination regimens?

Why do clinicians managing patients with T2D need to be aware of the trials, physiologic basis, side effects and other dimensions of deploying fixed ratio, long-acting insulin-GLP-1 RA combination regimens?

What are the clinical implications of the fact that liraglutide’s benefits were seen in a high risk population that was already on maximal therapy for CV risk reduction?

What are the clinical implications of the fact that liraglutide’s benefits were seen in a high risk population that was already on maximal therapy for CV risk reduction?

What are the clinical implications of the fact that liraglutide’s benefits were seen in a high risk population that was already on maximal therapy for CV risk reduction?